Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1822]
News [2728]
Articles [201]
Editorials [1]
Conferences [136]
elearning [13]
Sotorasib demonstrates superior PFS vs docetaxel for previously treated non...
Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA
Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation ( Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA )
12 Sep 2022
Emerging systemic therapies in rare urothelial cancer variants
Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA
Emerging systemic therapies in rare urothelial cancer variants ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )
12 Sep 2022
ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer
Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike...
ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer ( Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann )
11 Sep 2022
Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for...
Dr Silvia Novello - University of Turin, Turin, Italy
Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for squamous NSCLC ( Dr Silvia Novello - University of Turin, Turin, Italy )
11 Sep 2022
Lenvatinib remains standard of care for first-line therapy in advanced...
Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA
Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )
11 Sep 2022
Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC...
Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San...
Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )
11 Sep 2022
Atezolizumab added to chemo fails to improve PFS in relapsed ovarian cancer
Prof Jean Emmanuel Kurtz - Strasbourg Cancer Institute, Strasbourg, France
Atezolizumab added to chemo fails to improve PFS in relapsed ovarian cancer ( Prof Jean Emmanuel Kurtz - Strasbourg Cancer Institute, Strasbourg, France )
10 Sep 2022
Topics under discussion at the WCLC 2022 presidential symposium
Dr Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain
Topics under discussion at the WCLC 2022 presidential symposium ( Dr Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain )
9 Aug 2022
Atezolizumab vs best supportive care in resected NSCLC
Dr Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain
Atezolizumab vs best supportive care in resected NSCLC ( Dr Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain )
9 Aug 2022
Working to improve global cancer care access in low middle-income countries
Dr Julie Gralow, Prof Eduardo Cazap
Working to improve global cancer care access in low middle-income countries ( Dr Julie Gralow, Prof Eduardo Cazap )
25 Jul 2022
Low-dose nivolumab leads to improved overall survival for head and neck cancer...
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Low-dose nivolumab leads to improved overall survival for head and neck cancer patients ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
19 Jul 2022
Updates from the PROpel and MAGNITUDE studies
Prof Phil Cornford and Dr Elena Castro
Updates from the PROpel and MAGNITUDE studies ( Prof Phil Cornford and Dr Elena Castro )
11 Jul 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation